Navigation Links
Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
Date:4/30/2008

o Xylocaine(R) alone (see table 1).

In addition, TPM/Lidocaine was able to increase the depth of lidocaine penetration. A significant (p < 0.001) increase of approximately 500% in lidocaine was detected in the thigh muscle of animals treated with TPM/Lidocaine over Xylocaine(R) alone.

Importantly, the increases in lidocaine delivery to both skin and muscle did not lead to a significant increase in systemic exposure. The average plasma lidocaine concentration peaked 1 hour after the topical application for both TPM/Lidocaine and Xylocaine(R). The differences in plasma concentration were not statistically significant. This is particularly impressive given the magnitude of the differences in the lidocaine concentrations in both skin and muscle.

These results show that TPM has the potential to be used as a targeted, localised delivery system, capable of increased delivery of therapeutic levels of lidocaine, and very likely other products, to targeted areas while minimising exposure to the rest of the body.

Mean lidocaine levels in tissue and plasma following treatment

Treatment Skin Thigh Plasma Concentration

(micrograms) (micrograms) (ng/ml)

Xylocaine(R) 5% 1.47 +/- 0.65 0.11 +/- 0.03 54.17 +/- 26.22

TPM/Lidocaine 5% 13.46 +/- 2.23 0.59 +/- 0.10 77.46 +/- 38.38

Table 1

Dr. Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "We are excited by the prospect of being a global competitor in such a large market, with global sales of topical local anesthetics for the year ended 30 June 2007 reaching U.S. $1.2 billion. Our technology has shown the potential to substantially enhance the current standard of care."

Harry Rosen, President and CEO at Phosphagenics, said "Commercially, a portfolio of topically delivered products offers a number of ad
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
2. Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
3. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
4. Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
5. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... N.J. , March 5, 2015 CANTEL MEDICAL ... for its second quarter ended January 31, 2015 on Thursday, ... call to discuss the results at 11:00 AM ET. ... 407-8033 approximately 5 to 10 minutes before the beginning of ... replay of the call will be available from Thursday, March ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... WALTHAM, Mass., Jan. 4, 2011 Syndax Pharmaceuticals, Inc., ... Horobin, M.D., the company,s president and CEO, will present ... 2011 at 10:00 a.m. PT at the Parc 55 ... include the recently reported results from a randomized phase ...
... Jan. 4, 2011 STAAR Surgical Company (Nasdaq: ... and marketer of minimally invasive ophthalmic products, today ... ICL implants in patients has exceeded 200,000.  Since ... used in refractive eye surgery as an alternative ...
Cached Medicine Technology:STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 2STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 3
(Date:3/6/2015)... 06, 2015 Dr. Amy Reed, who together ... ban on the use of power morcellators ( http://www.morcellatorlawsuit2015.com ) ... cancer that prompted the launch of their public health campaign. ... that the 41-year-old mother of six had recently undergone surgery ... her spine. Dr. Reed had been in remission for about ...
(Date:3/6/2015)... Ticket Down is a reliable source for authentic ... Clara, California. This state-of-the-art stadium opened on July 17, ... events. , The “Kick the Dust Up Tour” featuring country ... the west coast and Levi’s Stadium. The show at the ... August 29 and fans of the award-winning artist will be ...
(Date:3/6/2015)... 06, 2015 Follow us on ... most common forms of cancer and is the leading ... be screened through various techniques and tools, including mammography, ... the gold standard technique in breast cancer screening, driven ... taken for the procedure, required expertise to carry out ...
(Date:3/6/2015)... Ticket Down is a reputable source for authentic ... their customer appreciation discount code ED-SHEERAN-2015 for added savings. , ... he began his career in the music industry 10 years ... Ed Sheeran has become a household name. , It ... is having the time of his life and his audiences ...
(Date:3/6/2015)... Further solidifying their position as a ... today that the company has earned Inavero’s Best of ... Staffing Talent Award five years in a row. Presented ... Diamond winners are proven industry leaders in service quality ... individuals they have helped find temporary and permanent jobs. ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 2Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 3Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 4Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 3
... removed from product -, WAYNE, N.J., May 19 ... of the liquid Leukine(R),(sargramostim) 500 mcg vial has been ... and is now available for patients and physicians,in the ... disodium),which was in the product,s liquid 500 mcg vial ...
... census, Americans office workers spend an average of 52 ... Many recent studies on job satisfaction have shown that ... under artificial light in windowless offices, report reduced job ... make office environments more conducive to productivity and employee ...
... initiation and progression of prostate cancer have eluded ... researchers have identified a specific gene expression profile ... for future treatments. The findings, published in BioMed ... genes that are differentially expressed in certain prostate ...
... VIEW, Calif., May 19 Alexza,Pharmaceuticals, Inc. ... Jeffrey S.,Williams has rejoined the company in ... Ltd., a wholly owned subsidiary of Alexza. ... the Alexza,subsidiary in Singapore and establishing potential ...
... LLC, the world,s,first mobile voice-activation solution for e-Health ... J. Zecchini as its Chief,Operating Officer and Chief ... be responsible for all operations and technology functions., ... to our MediVoice team," said,Anthony V. Milone, Board ...
... CLARA, Calif., May 19 FLARE Santa,Clara HIV ... (AACI), The Billy DeFrank Center Lesbian and Gay ... Health Department, Asian,& Pacific Islander Wellness Center present ... Thursday, May 22, 2008 from 11 to 2 ...
Cached Medicine News:Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 2Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 3Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 4Health News:Greener offices make happier employees 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3Health News:MediVoice Announces Appointment of Edward J. Zecchini as Chief Operating Officer & Chief Technology Officer 2
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... Spectrophotometers are simple, reliable ... use in many types ... clinical, industrial and environmental ... vial holders, Windows based ...
Spectra 5000 is one of the most versatile analytical devices used in conventional laboratories which can work in the ultravoilet and visible range from 200 to 1000 nm for quantitative and qualitative...
... 400 Series Spectrophotometer ... approach to UV-VIS instrumentation. ... are incorporated into a ... in features and performance ...
Medicine Products: